(Baltimore, MD--May 14, 2013) Noxilizer, Inc., the company behind the unique and superior, room temperature NO₂-based sterilization technology for life science manufacturers and hospitals, announced today the appointment of Mr. David Chaskin as CFO.

Mr. Chaskin, the first of several planned hires to support Noxilizer’s expansion and will be responsible for all aspects of the company's finance and accounting. President and CEO, Larry Bruder said, “Noxilizer is poised for growth. We have a clear commercialization plan and David will be a key member of our leadership team in support of our plan and advancing NO₂ sterilization in the global marketplace. David has a deep knowledge of finance, accounting, and operations and understands how to take organizations to the next level.”

Mr. Chaskin brings over 25 years of accounting and financial reporting experience in a variety of strategic and financial executive roles. Most recently, he served as CFO for Aritas Group, Inc., a financial holding company, and the Financial and Operations Principal for the US broker dealer subsidiary, Aritas Securities LLC. Mr. Chaskin joined Aritas Group, Inc. a few months after its initial product launch and helped it grow into a company that achieved tens of millions of dollars of revenue. Prior to Aritas, he held a variety of financial roles for large, publicly-traded companies including Chemical Bank, Guess? and TBA Entertainment, and lead financial positions with smaller, privately-held companies.

Of the opportunity, Mr. Chaskin notes “Noxilizer, Inc. has a solid financial position, and is bringing a superior offering to the sterilization marketplace. There is incredible opportunity as the commercial team articulates the advantages of NO₂ sterilization and delivers on customer needs, to grow revenue and build shareholder value.” The only room temperature sterilization solution, NO₂ sterilization is highly-compatible with a wide range of drug-device products, and provides a safer, simpler, more economical alternative for manufacturers.

Also in support of the increased commercial activities, Noxilizer recently relocated to a 16,000 square foot office and laboratory space at the University of Maryland BioPark.

“Our new lab space allows us to respond to a growing number of inquiries for feasibility studies, increasing demand for our contract sterilization services, and ramp up production of the RTS 360 Industrial NO₂ Sterilizer.” says Bruder. Additionally, it provides Noxilizer growing room as we advance our hospital program.” Noxilizer’s new headquarters is located at 800 West Baltimore Street, Suite 151 Baltimore, MD 21201.

About Noxilizer, Inc.:

Noxilizer has a unique and superior room temperature NO₂-based sterilization technology that is revolutionizing two major sterilization markets — medical device/ pharmaceutical/biotechnology manufacturing and hospitals. In the manufacturing market, Noxilizer provides sterilization services for medical devices and drug/device combination products. Noxilizer sells the RTS 360 Industrial NO₂ Sterilizer to companies who sterilize products in-house and also offers contract sterilization services. In hospitals, Noxilizer is developing a system especially for sensitive, high-tech equipment used in minimally-invasive surgical procedures. Noxilizer is headquartered in Baltimore, MD with offices in the US and Japan. Noxilizer, Inc. is privately held and was founded in 2004. For more information about Noxilizer, please visit: www.noxilizer.com.

Media Contact:

Angie Kearns
Brand Manager
Noxilizer, Inc.
C (574) 304-1502
akearns@noxilizer.com

Click here to download pdf

[ back to top ]

Noxilizer Acquires Japanese-Based SAIAN Corporation Assets And Expands Nitrogen Dioxide Sterilization Product Line For Global Life Science Marketplace, March 1, 2013

Noxilizer increases product offering and accelerates commercialization activities to support pharmaceutical, biotech and medical device customers.

(Baltimore, MD and Wakayama-shi, Japan – March 1, 2013) Noxilizer, Inc. and SAIAN Corporation announced today Noxilizer’s asset acquisition of SAIAN Corporation. Both companies have been involved in developing nitrogen dioxide as a sterilization solution for pharmaceutical, biotech and medical device companies, as well as hospitals. The strategic acquisition is intended to strengthen the global effort to promote acceptance and growth of nitrogen dioxide sterilization as a powerful and less-expensive alternative to current sterilization methods.

Nitrogen dioxide (NO₂) sterilization technology represents one of the more important innovations in medical device sterilization in over 20 years. As a room temperature sterilization alternative to ethylene oxide (EO), gamma and hydrogen peroxide, Noxilizer provides an option for companies to save significant costs by safely sterilizing in house, allowing inventory release in just hours versus days. Other benefits provided by nitrogen dioxide sterilization include: a true room temperature process, improved materials compatibility, much faster cycle time and no concerns about residuals. All important factors as pharmaceutical, biotech and medical device companies continue to innovate and grow.

“Noxilizer’s acquisition of SAIAN Corporation assets will immediately bring an expanded line of NO₂ sterilization products to our customers in the pharmaceutical, biotech and medical device markets. SAIAN’s unique approach to providing sterilizers with onboard sterilant generation and abatement capability offers great advantages in room temperature sterilization which we believe will greatly benefit our customers. We are excited about the opportunity to introduce breakthrough sterilization technology as a means to improve customer productivity and build shareholder value. The agreement also establishes Noxilizer as a global player in the life science sterilization market, including the important Japanese market,” says Lawrence Bruder, President & CEO of Noxilizer, Inc.

“We are very excited to bring a strong product contribution to Noxilizer. Noxilizer has already developed a presence in the market and is generating revenue. The engineering team in Japan looks forward to working together,” says Ryuichi Iwasaki, formerly CEO of SAIAN and now General Manager, Noxilizer Japan KK. Ryuichi Iwasaki will lead the team in Japan and report to Lawrence Bruder.

SAIAN Corporation’s leading investor since inception is The University of Tokyo Edge Capital Co., Ltd. based in Tokyo, Japan. “We believe in the power of nitrogen dioxide sterilization and the ability to impact the pharmaceutical, biotech and medical device markets. The potential for both companies to be successful increases when they work as one. Our investment team has great confidence in the leadership and looks forward to continuously investing in the potential of nitrogen dioxide sterilization enabled by Noxilizer and combined with SAIAN assets, together with a wider range of investment groups in the US and Japan,” says Tomotaka (Tommy) Goji, Managing Partner & President of UTEC.

Noxilizer’s headquarters will continue to be in Baltimore, MD. Noxilizer Japan KK is a newly formed subsidiary located in Wakayama-shi, Japan.

About Noxilizer, Inc.:

Noxilizer has a unique and superior NO₂-based sterilization technology that is revolutionizing two major sterilization markets — pharmaceutical/biotechnology/medical device manufacturing and hospitals. In the manufacturing market, Noxilizer provides sterilization services for next generation medical devices and drug/device combination products. Noxilizer also sells the RTS 360 Industrial NO₂ Sterilizer to companies that sterilize their own products. In hospitals, Noxilizer is developing a system especially for the sensitive, high-tech equipment used in minimally-invasive surgical procedures. The company was founded in 2004 and is privately held. Investors include: CHV Capital in Indiana, Maryland Healthcare Product Development Corporation and the University of Tokyo Edge Capital Co., Ltd. (UTEC), as well as angel investors. Noxilizer is located at the University of Maryland Baltimore County Technology Center in Baltimore, MD and Wakayama-shi, Japan.

Media Contact:

Angela S. Kearns
Noxilizer, Inc.
C (574) 304-1502
akearns@noxilizer.com

Click here to download pdf

[ back to top ]

Noxilizer Achieves Key Milestones in Commercialization of Proprietary Sterilization Technology, November 15, 2012

Catheter Research Inc. of Indianapolis orders first Noxilizer RTS 360 Industrial NO₂ Sterilizer to provide contract sterilization services to global medical device companies

(Baltimore, MD--November 15, 2012) Noxilizer Inc. announced today that Catheter Research Inc. (CRI) (www.catheterresearch.com) based in Indianapolis, IN has ordered the RTS 360 Industrial NO₂ Sterilizer. CRI is a contract medical device manufacturer with customers who include global leaders in the industry. In addition to sterilizing their own devices, CRI will offer sterilization services to medical device companies located in the Midwest. The RTS 360 will be installed in January 2013.

Noxilizer’s proprietary low temperature sterilization technology is the first innovation in the industry in over 20 years. The advantages over existing modes of sterilization are: room temperature process, fast cycle time and improved worker safety over existing methods. The system allows for inventory release in hours versus weeks and cost savings of 40% to 60% for medical devices companies. Noxilizer sells the RTS 360 Industrial NO₂ Sterilizer directly to companies so that they can bring sterilization in house, as well as provides contract sterilization services.

This marks one of several important milestones that Noxilizer has recently achieved. Other accomplishments include:

Raised $3.5M and closed the Series B financing round. Investors included The Abell Foundation (www.abell.org) in Baltimore, MD. The success of the round was enhanced by investor participation in the Maryland Biotechnology Investment Tax Credit Program.
Featured cover story on Noxilizer’s technology in a prominent industry publication, Medical Design Briefs (September); and
Committed to move to the University of Maryland BioPark (www.umbiopark.com) in early 2013 to accommodate increasing staff, lab and manufacturing space.

“Noxilizer has entered the commercialization phase. Along with the contract sterilization services we provide in our Baltimore facility, the commitment of CRI and other prospective customers, Noxilizer is building a revenue stream, a strong foundation of growth and increased value for our shareholders,” says Lawrence Bruder, President & CEO.

About Noxilizer, Inc.:
Noxilizer has a unique and superior NO₂-based sterilization technology that is revolutionizing two major sterilization markets — medical device/pharmaceutical/biotechnology manufacturing and hospitals. In the manufacturing market, Noxilizer provides sterilization services for next generation medical devices, prefilled syringes and drug/device combination products. Noxilizer also sells the RTS 360 Industrial NO₂ Sterilizer to companies that want to sterilize their own products. In hospitals, Noxilizer is developing a system especially for the sensitive, high-tech equipment used in minimally-invasive surgical procedures. The company was founded in 2004 and is privately held. Noxilizer is located at the University of Maryland Baltimore County Technology Center in Baltimore, MD. For more information about Noxilizer, please visit: www.noxilizer.com.

Click here to download pdf

[ back to top ]

Firm sees sterilization as fertile business ground, Indianapolis Business Journal, October 15, 2012

To view online click here

Indianapolis-based medical-device maker Catheter Research Inc. will receive a new kind of sterilization machine in December that it hopes will reduce costs and wait times for medical-device companies in the Midwest—including itself.

Catheter will set up a new-generation sterilization machine made by Maryland-based Noxilizer Inc. The company’s lead investor is Indianapolis-based CHV Capital Inc., the venture capital arm of the Indiana University Health hospital system.

Sterilization is a required step, overseen by the U.S. Food and Drug Administration, in both the development and production of medical devices. In March, a new sterilization facility opened near Warsaw. But there are no contract sterilization facilities in the Indianapolis area.

Catheter Research, which makes catheter-based medical devices for itself and on contract for other companies, sends its products to sterilization facilities in either Illinois or Michigan. The total turnaround time is 10 days.

“It’s a long way and it’s expensive,” said John Steen, CEO of Catheter Research, which employs about 130 people on West 82nd Street in the Park 100 industrial park.

But the Noxilizer machine will cut that down to one day—and shave off about 40 percent to 60 percent of typical costs.

The $250,000 machine, which is about the dimensions of small family room in a house, uses nitrogen dioxide to sterilize medical devices. Inside the machine, the gas suffuses a medical device to kill off any bacteria and then gradually flows out of it in a process called out-gassing. One complete sterilization cycle runs about four hours.

But the most commonly used technology currently in use, known as ethylene oxide, takes days for out-gassing. It also costs the same amount of money to sterilize a pallet full of devices or just a few. So companies typically have to stockpile products before having enough to sterilize.

Neither the time nor the large batches are convenient for small companies trying to develop new products in small batches, which is a key reason having sterilization facilities has been a top item on the wish list of Indianapolis-based BioCrossroads, the life sciences development organization.

That’s why Catheter Research thinks it can use the Noxilizer machine to develop a new line of business in contract sterilization work.

“As the life sciences continue to grow here," said Phil Sheingold, vice president of operations at Catheter Research, “what we will be able to offer is a low-cost alternative to sterilization so that they don’t have their capital tied up in inventory.”

Kyle Salyers, managing director of CHV Capital, said Noxilizer’s technology is not as corrosive as ethylene oxide to medical devices made from polymers or that use optical technology in them. That difference, as well as the lower costs and quicker turnaround times, make it attractive to IU Health.

Noxilizer has yet to seek approval for its technology in hospitals, but it plans to do so by the end of 2013, said Larry Bruder, CEO of Noxilizer.

He also sees some market in the pharmaceutical industry, where injectible drugs are increasingly being packaged in pre-filled plastic syringes that need to be sterilized, typically with ethylene oxide.

In addition, he added, injectible drugs packaged in glass vials are usually topped with rubber stoppers. Ethylene oxide sometimes penetrates those stoppers, and then alter the drug inside the vial. But the nitrogen dioxide used by Noxilizer has no such effect.

Noxilizer’s joint venture with Catheter Research is the first of several regional hubs Noxilizer plans to set up across the nation to perform contract sterilization services.

“Contract sterilization is an $800 million business in the U.S. and Europe,” Bruder said, noting that about 45 percent of those dollars go to ethylene oxide. Another 45 percent pays for gamma radiation for sterilization, and Bruder thinks Noxilizer could be a good alternative for some of that business, too.

“We feel like we’re a really interesting alternative to ethylene oxide, and also some with gamma,” he said. “So we feel there’s an opportunity to grow a really significant business here.”

Click here to download pdf

[ back to top ]

Abell Foundation pumps $580K into two local companies, Baltimore Business Journal, September 7, 2012

To view online click here

Two area startups — one specializing in sterilizing medical equipment and another that has developed an online teacher’s aide — are the latest beneficiaries of a foundation established to bolster the local economy and promote social entrepreneurship.

The Abell Foundation is making a $500,000 investment in Noxilizer Inc., and in August it invested $80,000 in Common Curriculum. Foundation President Robert C. Embry Jr. said these investments reflect Abell’s mission of backing companies based in Baltimore — or which are willing to relocate here — that create jobs and produce socially worthwhile products and services.

The Abell Foundation — one of Baltimore’s best-known philanthropic groups, and one that traces its roots back to the 1950s — invests about 15 percent of its $320 million endowment, or roughly $48 million, in early-stage companies like Noxilizer. It currently has investments in about 15 companies, Embry said. That is in addition to the approximately $16 million in charitable grants the foundation gives out each year.

The program’s focus is on companies that do things like improve education or health, benefit the environment or develop renewable energy sources.

“We don’t invest in restaurants, or a new clothing line or computer apps,” Embry said.

Some of the other companies in which Abell currently has investments include:

BioMarker Strategies, which is developing a process for testing tumor samples at the point of biopsy. The company is based at the Johns Hopkins Science + Technology Park.
CeraTech Inc., a Baltimore company that has developed a form of cement made from recycled materials.
Pixelligent Technologies, a Baltimore nanotech company whose products are used in the solar power and electronics industries.

The foundation’s investments have typically ranged in size from $75,000 to $2.5 million.

Embry is emphatic that these are not charitable donations. In addition to creating jobs, the foundation expects its investments will yield a profit, Embry estimates the companies the foundation has invested in since 1995 have created more than 1,000 jobs.

“We have made more money from those investments than we have from our traditional investments,” Embry said, without providing specific returns. In exchange for its investment, Abell gets a stake in the company. Sometimes, its investment is in the form of a loan that is convertible into equity in the company.

Two of the companies Abell invested in — Guilford Pharmaceuticals and Visicue Inc., a maker of patient-monitoring systems for hospitals — have gone public.

The foundation’s investment in Noxilizer will help the 8-year-old company boost the size of its workforce and enter the market for sterilizing medical equipment for hospitals. Currently, Noxilizer targets pharmaceutical companies and medical device makers as customers.

Noxilizer plans to move from the technology park at the University of Maryland, Baltimore County into about 12,000 square feet of office and laboratory space at the University of Maryland Baltimore’s BioPark on the city’s west side. The move could come as early as the end of 2012, said Lawrence Bruder, Noxilizer’s CEO.

The company has 17 employees. Bruder is looking to hire at least five more people and grow the company to 50 in the next three years.

“We see it as quite an honor and an affirmation of our credibility,” Bruder said of Abell’s investment. “We have had other people coming to us because they heard about Abell’s investment to see if they can participate.”

Common Curriculum is a Baltimore company founded three years ago by two former Baltimore City teachers. The company has developed a tool for teachers to write their lesson plans online and share them with students, parents and other teachers.

“We see [improving education] as a social good, and they’re located here in Baltimore,” Embry said.

Abell’s investment, coupled with an investment by Bill Me Later co-founder Vincent Talbert, will help Common Curriculum hire software developers and market its product, said Scott Messinger, a Common Curriculum co-founder.

Messinger launched the company three years ago with business partner Robbie Earle. The company has lined up about 150 teachers to test its product and hopes to roll it out to paying customers by the 2013-2014 school year, Messinger said. Bill Me Later was bought by online auction giant ebay in 2008 for about $1 billion.

Messinger declined to specify the size of Talbert’s investment, but Embry put the figure at $80,000.

[ back to top ]

Noxilizer’s David Opie, Ph.D. to present at three industry conferences in Spring 2012

(Baltimore, MD – March 11, 2012) David Opie, Ph.D., Senior Vice President, Research & Development, has been invited to address three important industry conferences this spring:

Parenteral Drug Association (PDA) Annual Meeting, April 16 – 18, 2012 in Phoenix, AZ. David will be speaking, as well as presenting a scientific poster. Noxilizer will also have an exhibit booth at the conference.

Third Annual Pre-Filled Syringes Americas Meeting, May 14 – 16, 2012 in Boston, MA. David will be speaking at this meeting, along with representatives from: Pfizer, Genentech, Eli Lilly and Company and BD Medical – Pharmaceutical Systems.

2012 PDA Innovation & Best Practices on Sterile Technology Conference, June 18 – 19, 2012 in Chicago, IL. The theme of the conference is “Sterile Processes: Product Development.” David’s presentation is titled, “Nitrogen Dioxide as a Replacement for Ethylene Oxide for Medical Device Sterilization.”

About PDA:
Founded in 1946, PDA is a non-profit international association of more than 10,500 scientists involved in the development, manufacture, quality control and regulation of pharmaceuticals and related products. The association also provides educational opportunities for government and university sectors that have a vocational interest in pharmaceutical sciences and technology. The mission of PDA is to advance pharmaceutical and biopharmaceutical technology internationally by promoting scientifically sound and practical technical information and education for industry and regulatory agencies.

[ back to top ]

Sterilization Technology Group, Inc. (STG) Announces Next Generation Decontamination Technology and Generators for Use With Pharmaceutical and Biotechnology Manufacturing and Sterility Testing

(Cary, NC – February 3, 2012) Sterilization Technology Group, Inc. (STG) announced today plans to develop products for the decontamination of isolators, such as sterility testing enclosures and enclosed filling lines for the pharmaceutical and biotechnology industry. STG plans to manufacture both stand alone and integrated generator packages for this purpose along with supplying full validation services for its clients. STG has secured exclusive rights to use the proprietary and patented Noxilizer NO₂ gas technology. STG is responsible for the development, manufacturing, and commercialization of the decontamination generator.

Isolators and other related enclosures are an important part of any life science company’s manufacturing, Quality Control and R&D processes. The sealed areas are used to produce and/or test products in a decontaminated “germ-free” environment. Examples of typical product containers include: prefilled syringes and vials. Sterilant generators were developed in the late 1980’s to provide for a more effective and validatable decontamination process. Today, the majority of pharmaceutical and biotechnology companies utilize technologies based on vaporizing hydrogen peroxide. The NO₂ gas technology has been shown to dramatically reduce aeration time by as much as 85% when compared to the older vapor hydrogen peroxide technology while maintaining the necessary standards in the industry with regard to microbial kill and materials compatibility.

STG was founded by three (3) industry veterans who were instrumental in the initial launch of the original vaporized hydrogen peroxide generator.

“As 25-year veterans of this industry, we see real advantages the Noxilizer technology has over current process options. We believe customers will not only value the faster aeration times, but are currently looking for a process that is compatible with today’s advanced protein based drugs and biological products”, states Michael Ferguson, Business Director and a founder of STG. “With the industry experience of William (Bill) Little, Technical Director, and James Rickloff, Scientific Director, also founders, STG has the experience and knowledge to bring a ‘best in class’ product to market”.

“This licensing agreement further validates Noxilizer’s technology and its importance in solving challenges of infection control and decontamination in the life science industry. The Noxilizer team is excited to work with STG as we grow our business in the important isolator market,” says Lawrence Bruder, President & CEO of Noxilizer, Inc.

About Sterilization Technology Group, Inc. (STG)

STG was formed in 2006 to develop and market a superior method for decontamination of sealed enclosures for the pharmaceutical and biotechnology markets. The founders of STG have over 70 years of combined experience in developing novel technologies and in the validation of processes for FDA compliance in this industry. STG is designing and developing products that will surpass all current technologies with regard to aeration and cycle times without sacrificing microbiological kill rates or materials compatibility. STG feels the industry is looking for the “next generation” product to replace existing technologies that have not changed in over 20 years. STG is located in Cary, North Carolina with manufacturing capabilities in Wisconsin.

About Noxilizer, Inc.

Noxilizer has developed a unique and superior NO₂-based sterilization technology that will revolutionize two major sterilization markets — life science manufacturing and hospitals. In the life science market, Noxilizer provides sterilization services for next generation medical devices and drug/device combination products. Noxilizer also sells the RTS 360 NO₂ Industrial Sterilizer to life science companies. In hospitals, Noxilizer is developing a system especially for the sensitive, high-tech equipment increasingly used in minimally-invasive surgical procedures. The company was founded in 2004 and is privately held. Noxilizer is located at the University of Maryland Baltimore County Technology Center in Baltimore, MD.

Media Contact:

Michael Ferguson, Director Business Operations
Sterilization Technology Group, Inc.
(919) 649-0078
mferguson@steriletechgr.com

[ back to top ]

Noxilizer Licenses Sterilization Technology to Eniware for Developing World and Related Markets

February 27, 2012

PRESS RELEASE

NOXILIZER LICENSES STERILIZATION TECHNOLOGY TO ENIWARE FOR DEVELOPING WORLD AND RELATED MARKETS

Eniware to develop Noxilizer sterilization technology for developing world, first responder and military applications.

(Baltimore, MD and Washington, DC – February 27, 2012) Noxilizer, Inc. and Eniware LLC announced an agreement today to develop portable, power-independent medical device sterilization units for the developing world, disaster response, and military markets. Noxilizer is licensing its proprietary nitrogen dioxide sterilization technology. Eniware will be responsible for the development, manufacturing, and commercialization of this product line.

Infection and disease transmission in clinics and hospitals afflict millions in the developing world. Sterile medical instruments can mean the difference between life and death. Reported healthcare-related infection (HRI) rates in developing countries range from 15% to 40% or more. This problem only grows as access to healthcare grows, particularly with the expansion of simple, basic surgery in under-resourced settings. Potentially lifesaving procedures tragically cripple or kill millions of men, women, and children due to lack of affordable, effective sterilization of medical equipment. With the introduction of power-independent sterilization units, there is an opportunity to reduce the incidence of infection and save lives anywhere, at any time.

“This licensing agreement further validates Noxilizer’s technology and its importance in solving a variety of sterilization needs – including the most challenging of environments. Our partnership with Eniware will enable sterilization solutions that improve the quality of medical care and reduce the incidence of infection for people who do not have immediate access to a fully-equipped hospital,” says Lawrence Bruder, President & CEO of Noxilizer, Inc.

“As a physician, I know how important the sterilization issue is in any medical setting, and especially in the developing world, disaster areas and on the battlefield. The opportunity to use my medical and business experience to solve this problem is the opportunity of a lifetime,” states James Bernstein, MD, President & CEO of Eniware LLC.

Eniware is in the process of finalizing funding for the development effort. Potential customers include: global health organizations, governments of developing countries, global first responder organizations, and militaries.

About Noxilizer, Inc.:

Noxilizer has a unique and superior NO₂-based sterilization technology that is revolutionizing two major sterilization markets — medical device/pharmaceutical/biotechnology manufacturing and hospitals. In the manufacturing market, Noxilizer provides sterilization services for next generation medical devices and drug/device combination products. Noxilizer also sells the RTS 360 NO₂ Sterilization System to companies that sterilize their own products. In hospitals, Noxilizer is developing a system especially for the sensitive, high-tech equipment used in minimally-invasive surgical procedures. The company was founded in 2004 and is privately held. Noxilizer is located at the University of Maryland Baltimore County Technology Center in Baltimore, MD.

About Eniware LLC:

Eniware LLC is a privately-held company based in Washington, DC. Formed in 2011, Eniware is committed to bringing critical sterilization technology to the developing world, first responders, and militaries.

Media Contacts:.
Maura O. Kahn
Vice President, Business Development & Marketing
Noxilizer, Inc.
O (443) 543-5783
M (202) 744-6337
mokahn@noxilizer.com

Eric Verkerke
Director of Communications & Product Development
Eniware, LLC
(434) 260-1809
Eric.Verkerke@EniwareSterile.com

[ back to top ]

Noxilizer Licenses Technology to STG for Key Science Market

June 22, 2011

Media Contact:
Maura O. Kahn
Vice President, Business Development & Marketing
Noxilizer, Inc.
O (443) 543-5783
mokahn@noxilizer.com

PRESS RELEASE

NOXILIZER LICENSES TECHNOLOGY TO STG FOR KEY LIFE SCIENCE MARKET
STG to develop Noxilizer technology for global decontamination generator opportunities.

(Baltimore, MD and Cary, NC -- June 22, 2011) Noxilizer, Inc. and Sterilization Technology Group, Inc. (STG) announced today an agreement to develop products for the isolator generator market. Noxilizer is licensing its proprietary nitrogen dioxide technology. STG will be responsible for the development, manufacturing and commercialization of this product line.

Isolators and other related enclosures are an important part of any life science company’s manufacturing and research and development process. The closed areas are used to produce products in a decontaminated environment. Examples of products include: prefilled syringes and insulin vials. Sterilant generators were developed in the late 1980’s to provide more effective decontamination. Today, the STERIS Corporation (Mentor, OH) and Skan AG (Switzerland) are the leading companies in the isolator decontamination generator market. Both companies utilize hydrogen peroxide.

“This licensing agreement further validates Noxilizer’s technology and its importance in solving challenges of infection control and decontamination. The Noxilizer team is excited to work with STG as we grow our business in the important isolator market,” says Lawrence Bruder, President & CEO of Noxilizer, Inc.

“As a 30-year veteran of this industry, I see real advantages that the Noxilizer technology has over the current process options. We believe customers will value the faster aeration time and improved material compatibility,” states Michael Ferguson, Business Director of STG.

A sterilant generator is in the development stage and will go through additional testing this year. Potential customers include: pharmaceutical and biotech companies, research and development, manufacturing and quality control groups.

About Noxilizer, Inc.:
Noxilizer has developed a unique and superior sterilization technology that will revolutionize two major sterilization markets — hospitals and life science manufacturing. In hospitals, Noxilizer is developing a system especially for the sensitive, high-tech equipment increasingly used in minimally-invasive surgical procedures. In the life science market, Noxilizer provides sterilization services for next generation therapies and medical devices. The company was founded in 2004 and is privately held. Noxilizer is located at the University of Maryland Baltimore County Technology Center in Baltimore, MD.

About Sterilization Technology Group, Inc. (STG):
STG was formed in 2006 to develop and market a superior method for decontamination of sealed enclosures for the pharmaceutical and biotechnology markets. The founders of STG have over 70 years of combined experience in developing novel technologies and in the validation of processes for FDA compliance in this industry. STG is designing and developing products that will surpass all current technologies with regard to aeration and cycle times without sacrificing microbiological kill rates or materials compatibility. STG feels the industry is looking for a “next generation” product to replace existing technologies that have not changed in over 20 years. STG is located in Cary, North Carolina with manufacturing in Wisconsin.

[ back to top ]

Noxilizer to present poster and exhibit at INTERPHEX 2011

March 10, 2011

Noxilizer has been selected to present a poster on the company's NO₂ sterilization technology at INTERPHEX 2011, March 29 - 31, 2011 at the Jacob K. Javits Convention Center in New York City, NY. In addition, the company will be exhibiting along with 650+ of the leading global life science manufacturing companies. Noxilizer will be located in the Manufacturing and Packaging area of the exhibit hall in booth #3083.

This will be Noxilizer's first formal introduction to the Life Science manufacturing industry. Anticipated attendance at this year's meeting will be 8,000 industry leaders. For more information about Noxilizer, please contact:

Maura O. Kahn, Vice President, Business Development and Marketing
Noxilizer, Inc.
1450 South Rolling Road
Baltimore, MD 21227
O (443) 543-5783
C (202) 744-6337
F (866) 316-7791
mokahn@noxilizer.com
www.noxilizer.com

About INTERPHEX INTERPHEX USA is the world's most trusted source for leading-edge technology, education, and sourcing of the products and services that drive scientific innovation for Life Sciences manufacturing. INTERPHEX 2011 will provide the latest information to influential leaders in life sciences through unique combinations of conference, exhibition, workshops, partnering opportunities, and networking events.

[ back to top ]

Noxilizer to Present at AdvaMed 2010 and Mid-Atlantic Bio

October 18, 2010

Noxilizer technology to be presented to health care leaders and investors.

(Baltimore, MD -- October 18, 2010) Noxilizer, Inc. has been selected to present at two of the leading health care meetings: AdvaMed 2010 and Mid-Atlantic BIO. The presentation at AdvaMed 2010 will be on October 20, 2010 at 9:30am in Room 204A during the international meeting being held at the Walter E. Washington Convention Center in Washington, DC. Noxilizer’s presentation at Mid-Atlantic BIO will be on October 28th at 10am at the Bethesda North Marriott in Bethesda, MD.

“ To be selected to present at these two prominent meetings of medical device and biotechnology leaders is a huge compliment to Noxilizer and further validates our enabling technology,” says Lawrence Bruder, Noxilizer’s President & CEO.

Noxilizer has developed the first new low temperature sterilization technology in over 15 years. The company is targeting two large markets: hospitals and life science manufacturing. Mr. Bruder continues, “Every month, we receive calls from companies that have developed the next generation bioresorbable implant or sophisticated endoscope and they are not satisfied with current sterilization options. The Noxilizer sterilization technology may provide a new option for these companies and support continued innovation.”

About Noxilzer, Inc.:
Noxilizer is pioneering the development of a unique and superior sterilization technology that will revolutionize two major sterilization markets — hospitals and life science manufacturing. In hospitals, Noxilizer is developing a system especially for the sensitive high-tech equipment increasingly used in minimally invasive surgical procedures. In the life science market, the development of next generation therapies and medical devices is constrained by current sterilization technologies. Noxilizer’s advantages include: more gentle and lethal sterilization, safe for workers and the ability to sterilize long lumens used in minimally invasive surgery and other procedures. Noxilizer is committed to providing innovative solutions for healthcare professionals and their patients. The company was founded in 2004 and is privately held. Noxilizer is located at the University of Maryland Baltimore County Technology Center in Baltimore, MD. For more information, visit: www.noxilizer.com.

About AdvaMed 2010:
AdvaMed 2010 is the premier MedTech conference for business leaders, entrepreneurs, policy-makers, media, financiers, and other industry stakeholders from around the world. In only its third year, AdvaMed 2009 attracted 1,400 industry leaders – including 500+ CEOs, Presidents and C-level executives. In today’s economic and political climate, AdvaMed 2010 is this year’s can’t miss MedTech event for networking; conducting partnering meetings; influencing policymakers and the media; and participating in educational sessions. Whether you need to finance, partner, or license technology; learn the latest important developments in reimbursement, regulatory, legal, intellectual property, and other critical areas; or meet with and hear from leaders in the Obama Administration and Congress, AdvaMed 2010 is your introduction to key decision-makers. For more information, visit http://www.AdvaMed2010.com.

About Mid-Atlantic BIO
The Mid-Atlantic Bio Conference, scheduled October 27-29, 2010, in Bethesda, Maryland, is co-hosted by the Tech Council of Maryland (TCM), the Mid-Atlantic Venture Association (MAVA), and the Virginia Biotechnology Association (VaBIO). Mid-Atlantic Bio benefits from broad regional support from the investor and greater business communities, academic institutions, government agencies, and partnering regional associations. For more information, or to register or sponsor, please visit www.midatlanticbio.org.

[ back to top ]

Mid-Atlantic Bio Conference Reveals Companies Selected to Present at October Conference

October 12, 2010

WASHINGTON D.C. (October 12, 2010)—Mid-Atlantic Bio today announced a much anticipated line-up of companies selected to present at their upcoming 2010 Mid-Atlantic Bio Conference, being held October 27-29 at the North Bethesda Marriott Convention Center in Bethesda, Md. Dedicated to promoting the biotechnology industry in the Mid-Atlantic region, the conference is hosted collectively by the region’s most influential bioscience and investor associations, the Mid-Atlantic Venture Association (MAVA), the Tech Council of Maryland/MdBio (MdBio) and the Virginia Biotechnology Association (VaBIO).

Each year at Mid-Atlantic Bio, a limited number of life science companies are chosen to present before a sought-after audience that includes a variety of capital sources, from corporate business development professionals to venture capitalists, angel investors, and various other qualified financing sources along with important industry professionals, peer scientists, company leaders and potential strategic partners. Over the past seven years, more than 1,200 companies have participated in Mid-Atlantic Bio, with more than 100 of those as presenters on the program, resulting in hundreds of millions in private financings and corporate investments, M&A activities, strategic partnerships and industry collaborations.

This year’s conference features three tracks that will highlight the company presenters that were chosen including the Showcase track, Emerging Growth track and a newly added First Look/Fast Pitch track. The companies chosen specialize in medical devices, health care IT, diagnostics, drug development, pharmaceuticals, biotherapeutics, biopharmaceuticals, therapeutics and gene therapeutics.

“Hearing the scientific advances and business cases directly from some of the leading seasoned and newly formed enterprises adds richness to this conference that is extremely powerful,” says Julia Spicer, Executive Director of the Mid-Atlantic Venture Association (MAVA). “Showcasing companies at various stages of development encourages future innovation as well as connections that foster investment opportunities, collaboration and partnering and the sharing of best practices – all at the core of Mid-Atlantic Bio.”

To be selected for a speaking spot at the conference, companies went through a multi-phase application review and competitive selection process. Numerous companies applied and were judged against such criteria as scientific interest, technology innovation, stage of development, addressable market, or recent enterprise advances and milestones achieved.

The following companies were chosen to present within each track:

Showcase:
• Argos Therapeutics of Durham, NC
• Sucampo Pharmaceuticals, Inc. of Bethesda, MD
• Supernus Pharmaceuticals of Rockville, MD
• TetraLogic Pharmaceuticals of Malvern, PA
• Zyngenia of Gaithersburg, MD

Emerging Growth:
• AFrame Digital of Reston, VA
• Ceres Nanosciences of Manassas, VA
• CSA Medical of Baltimore, MD
• Envisionier Medical Technologies, Inc. of Woodstock, GA
• Functional Genetics of Gaithersburg, MD
• NexGen Medical Systems, Inc. of Melbourne, FL
• Noxilizer of Baltimore, MD
• Plasmonix, Inc. of Baltimore, MD
• Sequella Inc. of Rockville, MD
• Sirnaomics, Inc. of Gaithersburg, MD
• TAU Therapeutics of Charlottesville, VA

First Look/Fast Pitch:
• Altammune, Inc. of Baltimore, MD
• Audiodontics of Bethesda, MD
• Creatv MicroTech, Inc. of Potomac, MD
• CW Optics, Inc. of Seaford, VA
• EncephRx of Baltimore, MD
• RAFAGEN, Inc. of Rockville, MD
• Seguro Surgical of Columbia, MD
• Seneb Biosciences of Doylestown, PA
• Techulon of Blacksburg, VA

Amita Shukla, Principal of New Enterprise Associates and member of the 2010 Selection Committee, notes that “The Selection Committee, with input from a qualified cross-section of industry and investor sources, is pleased to present a line-up of multi-staged companies this year, each with a unique opportunity to explore.”

Now in its seventh year, Mid-Atlantic Bio is the only globally-focused, yet regionally-based, event to combine components of a bioscience industry convention with an investor conference under one roof. More than 800 national and international industry leaders, government representatives, executives, researchers, investors, entrepreneurs, and professional services firms will gather to promote networking, business expansion, and technical-knowledge sharing. Home to industry-critical regulatory and research agencies; federal policymaking; and business and scientific centers of excellence, the Mid-Atlantic is a unique center for the global bioscience industry.

Conference Sessions:
Designed to be a platform that brings together science, company builders, commercial interests and collaborators, capital sources, and federal and regulatory thought-leaders, the 2010 program includes a variety of important industry topics—ranging from the latest in policy and regulatory matters, business and financing opportunities, and CEO War Stories to advances in science and technology—and showcases exciting companies from the biosciences field. A few of the highlighted sessions include:

• Building a Workforce Culture Around Commercialization
• Corporate Venture and Early Stage Partnerships
• Regulation and Reimbursement in a World of Changing Policies, Laws and Procedures
• New Science Technologies: Regional Successes
• An Insider’s View on Washington
• Synthetic Biology – Applications and Implications
• Accessing the Regulatory Risk: Your Path to Approval
• CEO War Stories: A Roundtable
• Plenary presentations by John Castellani, President and CEO of PhRMA, John F. Crowley, JD, MBA, Chairman and CEO of Amicus Therapeutics; Frederick Frank, Vice Chairman, Peter J. Solomon Company; James Greenwood, President and CEO of BIO; Martine A. Rothblatt, PhD, JD, MBA, Chairman and CEO of United Therapeutics Corporation; Joshua M. Sharfstein, MD, Principal Deputy Commissioner, U.S. Food and Drug Administration; and H. Thomas Watkins, President and CEO, Human Genome Sciences

BioMatch:
Mid-Atlantic Bio’s signature networking program, BioMatch, is designed specifically for the life sciences and biotech industries, and provides registered attendees access to advanced partnering software that facilitates personalized, one-on-one meetings between the leading bioscience organizations and industry leaders.

Partial List of Conference Sponsors:
Human Genome Sciences, Maryland Biotechnology Center, MedImmune, Biotechnology Industry Organization, Cooley LLP, Grand Thornton LLP, Hogan Lovells, Wilson Sonsini Goodrich & Rosati, BioMed Realty Trust, Inc., BDO, Alexandria Real Estate Equities, Inc., Janelia Farms Research Campus of Howard Hughes Medical Institute, NIH Federal Credit Union, George Mason University, Virginia Tech, James Madison University, Broad Oak Partners, H.I.G. BioVentures, CIT Gap Funds, Intersouth Partners, New Enterprises Associates, Oxford Finance, TEDCO, Third Security, LLC. See the complete listing of sponsors.

ABOUT MID-ATLANTIC BIO
The Mid-Atlantic Bio Conference, scheduled October 27-29, 2010, in Bethesda, Maryland, is co-hosted by the Tech Council of Maryland/MdBio (TCM/MdBio), the Mid-Atlantic Venture Association (MAVA), and the Virginia Biotechnology Association (VaBIO). Mid-Atlantic Bio benefits from broad regional support from the investor and greater business communities, academic institutions, government agencies, and partnering regional associations. For more information, or to register or sponsor, please visit www.midatlanticbio.org. You may read the article here.

[ back to top ]

More than 60 innovative medical technology companies have been competitively selected to present company profiles

October 6, 2010

More than 60 innovative medical technology companies have been competitively selected to present company profiles before potential investors, partners and industry stakeholders, October 19 and 20 at AdvaMed 2010: The MedTech Conference. Selected companies represent innovation at all stages of development from various medical device sectors, and come from across the United States, Austria, Canada, Chile, Israel, Luxembourg, Switzerland and the United Kingdom. New this year are 20 company presentations from Coulter Foundation Translational Research Partnership Universities and two “Funding Forums” to highlight venture capital and government funding opportunities for emerging growth and established companies.

“ We have selected a diverse group of companies with technologies that range from addressing traumatic brain injuries with medical neurotechnology to photonic tumor therapy and everything in-between,” said Etienne Lagace, a Principal of Inovia Healthcare Ventures of Canada and a member of the AdvaMed 2010 company presentation selection committee. “These presentations and funding forums will provide companies with insights into the latest and most innovative technologies of today and tomorrow, as well as the funding opportunities available to develop these new, life saving and life changing medical devices. As an investor and an industry stakeholder, I look forward to hearing from all the companies and academic entrepreneurs.”

AdvaMed 2010 presenting companies include the following:
• 4ibio, Pickering, Ontario, Canada
• 20/20 GeneSystems, Inc., Rockville, Maryland
• Activiews, Inc., Lynnfield, Massachusetts
• Advanced Dental Technology, Richmond, Virginia
• Altrika, Inc. Sheffield, United Kingdom
• Alverix, Inc., San Jose, California
• AMES Technology, Inc., Portland, Oregon
• Avancen MOD Corporation, Mount Pleasant, South Carolina
• Biocompatibles International plc., Farnham, United Kingdom
• BrainScope Company, Inc., Bethesda, Maryland
• Calgary Scientific Inc., Calgary, Alberta, Canada
• CerviLenz, Inc, Chagrin Falls, Ohio
• Circuport, Inc., Morristown, New Jersey
• Claro Scientific, St. Petersburg, Florida
• Cohera Medical, Inc., Pittsburgh, Pennsylvania
• CogniSens, Montreal, Quebec, Canada
• ConvaTec Inc., Skillman, New Jersey
• CSA Medical, Baltimore, Maryland
• CytoPherx, Inc, Ann Arbor, Michigan
• CytoSorbents Corporation, Monmouth Junction, New Jersey
• DioGenix, Gaithersburg, Maryland
• eSight Corporation, Ottawa, Ontario, Canada
• EastMed Inc, Halifax, Nova Scotia, Canada
• Echometrix, Madison, Wisconsin
• EGI, Eugene, Oregon
• Endosense SA, Geneva, Switzerland
• Endomimetrics, Birmingham, Alabama
• Flowsense Medical Ltd., Misgav, Israel
• GeneEx, Inc., Hialech, Florida
• Hadasit Medical Research Services & Development Ltd., Jerusalem, Israel
• Healionics Corporation, Seattle, Washington
• Healthpoint, Ltd., Fort Worth, Texas
• Interface Biologics, Toronto, Ontario, Canada
• Jabil, Inc., St. Petersburg, Florida
• Lineagen, Inc., Salt Lake City, Utah
• MONITOR-it S.A., Esch-sur-alzette, Luxembourg
• NovaScan, Milwaukee, Wisconsin
• Noxilizer, Inc, Baltimore, Maryland
• Oncoscope, Inc, Durham, N. Carolina
• Photo Dynamic Therapy LLC, Vienna, Austria
• Profound Medical Inc., Toronto, Ontario, Canada
• Regenesis Biomedical Inc, Scottsdale, Arizona
• S.E.A. Medical Systems, Inc, Santa Clara, California
• Semprus BioSciences, Cambridge, Massachusetts
• SendSor Group, Lafayette, Indiana
• Sphere Medical, Cambridge, United Kingdom
• StemCellRX, Chile
• Tissue Fusion, LLC, Colorado Springs, Colorado
• TrusTech, Manchester, England
• ValveXchange, Inc., Aurora, Colorado
• ZSX Medical, LLC, King of Prussia, Pennsylvania

In addition to the companies listed above, from 2:50 p.m. to 4:50 p.m. Tuesday, October 19, the Coulter Foundation Translational Research Partnership Universities Boston University, Case Western Reserve University, Duke University, Georgia Institute of Technology and Emory University, Stanford University, University of Michigan, University of Maryland, University of Virginia, University of Washington and University of Wisconsin will present 20 innovative and exciting advances solving pressing, unmet clinical needs. These presentations will focus on advances in the following areas cardiovascular, IVD diagnostics, imaging, neurology, ophthalmology, orthopedics, surgical tools, tissue regeneration and wound healing.

“ To further assist emerging growth companies and foster innovation, AdvaMed 2010 will host two funding forums on Tuesday, October 19,” said Mr. Richard Holdren, a Texas-based angel investor with Healthcare Angels and AdvaMed 2010 Business Development Committee member. The two forums are titled “Tap Into $2 Billion in Government Funding” and “Venture Funding.” “These forums will focus on the SBIR and STTR federal small business grant and contract programs and today’s venture capital investment environment,” Holdren said.

Pete Shagory, Principal with Baird Venture Partners will lead the Venture Funding forum. Both the National Venture Capital Association and the Angel Capital Association support AdvaMed 2010: The MedTech Conference activities. You may read the article here.

[ back to top ]

Lawrence Bruder joins Noxilizer as President & Chief Executive Officer

July 2010

Noxilizer, Inc., a developer of next generation gas sterilization technology for hospitals and life science companies, announced the appointment of Lawrence Bruder as President & Chief Executive Officer.

“Larry brings over 25 years of leadership and operational experience in large and small life science companies. His successful track record in achieving value creating milestones, attracting investors and leading venture-backed companies made him an extremely attractive candidate,” said Lars Hanan, member, Noxilizer Board of Directors and Co-founder and Managing Partner at BroadOak Capital Partners.

Larry’s professional experience includes leadership positions at: Becton Dickinson, Applied Biosystems, Leica, Olympus, and Guava Technologies. Most recently he was President and CEO of venture-backed Guava Technologies, which was sold to Millipore Biosciences in 2009. Most of his experience prior to Guava was at Becton Dickinson, where he held a number of significant operational and leadership positions over a 10-year period. His responsibilities in both companies included the clinical and regulatory aspects of 510(k) submittals to the FDA for medical devices, significant commercial interaction with pharmaceutical companies, and high level business development transactional activity; all of these being a critical part of Noxilizer’s needs.

“I’m very excited to join the team at Noxilizer, as the core NO₂ sterilant technology will enable gentle, safe but effective low temperature sterilization of sensitive medical devices, such as pre-filled syringes, bioresorbable polymers and flexible endoscopes. The sterilization of these devices represents a huge global market opportunity for Noxilizer and I look forward to commercializing this capability within the hospital and life science marketplace, “said Larry Bruder.

Mr. Bruder holds a BS from Rochester Institute of Technology and Master of Management in Marketing & Economics from the Kellogg Graduate School at Northwestern University.

About Noxilzer:
Noxilizer is pioneering the development of a unique and superior sterilization technology that will revolutionize two major sterilization markets — hospitals and life science manufacturing. In hospitals, Noxilizer is developing a system especially for the sensitive high-tech equipment increasingly used in minimally invasive surgical procedures. In the life science market, the development of next generation therapies and medical devices for cardiovascular disease, cancer, and diabetes is constrained by current sterilization technologies which destroy chemical, biologic, and mechanical properties of many products. Noxilizer’s room-temperature system has shown great potential to be an enabling technology for a wide range of products, including antibodies, proteins, drug-device combination products, pre-filled syringes, bioresorbable polymers, nanoparticles and implants.

Advantages include: more gentle and lethal sterilization, safe for workers and the ability to sterilize long lumens used in minimally invasive surgery and other procedures.

Noxilizer is committed to providing innovative solutions for healthcare professionals and their patients. The company was founded in 2004 and is privately held. Noxilizer is located at the University of Maryland Baltimore County Technology Center in Baltimore, MD.

Contact:
Maura O. Kahn
Vice President of Business Development & Marketing
Noxilizer, Inc.
1450 South Rolling Road
Baltimore, MD 21227
(443) 543-5783
mokahn@noxilizer.com

[ back to top ]

Noxilizer’s breakthrough sterilization technology is featured in the March issue of Medical Device & Diagnostic Industry

Mar 2009

Noxilizer’s breakthrough sterilization technology is featured in the March issue of Medical Device & Diagnostic Industry (circulation 45,000). MD&DI is a monthly peer-reviewed journal written exclusively for manufacturers of medical devices and in vitro diagnostic products. You may read the article here.

[ back to top ]

Noxilizer Named One of 48 Top Innovators at the 2008 New England Venture Summit

Nov 2008

Noxilizer was selected as one of 48 Top Innovators at the 2008 New England Venture Summit. The summit was held on November 25th in Burlington, MA and brought together over 500 venture capital firms, angel investors, corporate venture capitalists, investment bankers and emerging companies. James Bernstein, MD, Chairman & CEO presented Noxilizer to the attendees.

[ back to top ]

Noxilizer Establishes Lab Space in University of Maryland–Baltimore County (UMBC) Technology Center

Oct 2008

In October 2008, Noxilizer signed an agreement to join the Incubator program at the University of Maryland, Baltimore County Technology Center. Noxilizer's R&D team has previously occupied sublet laboratory space at this location, where two of the Company's contract research labs providing chemistry and molecular biology support are located, allowing close collaboration among the extended R&D team. Now, as an Incubator Company, Noxilizer will have full access to UMBC's expertise, students, technology, programs and facilities.

[ back to top ]

Noxilizer Selected to Present at Life Sciences & Healthcare Venture Summit 2008 in New York City

Oct 2008

Noxilizer was one of 40 emerging companies selected to present at the Life Sciences & Healthcare Venture Summit 2008 held in New York City on October 30th. Twenty-five of the leading venture capital firms were in attendance, along with angel investors and corporate venture capitalists. The program showcased the leading health care investment opportunities in the United States. Marie-Louise Murville, President & COO, presented Noxilizer to the attendees.

[ back to top ]

Noxilizer Selected to Present at AdvaMed 2008

Sept 2008

Noxilizer was selected as a “Next Generation” company and presented at AdvaMed 2008 in Washington, DC on September 23rd. AdvaMed is the national trade association for medical device, diagnostic and health information system companies. These companies manufacture 90% of the health care technology produced annually in the United States and 50% of globally. This year’s meeting attracted over 400 companies and 1,100 attendees.

[ back to top ]

Noxilizer Announces Appointment of Maura Kahn as Vice President for Business Development and Marketing

May 2008

Noxilizer, Inc., a developer of next generation gas sterilization technology for hospitals and biotherapeutic products, announced the appointment of Maura Kahn as Vice President of Business Development and Marketing. Ms. Kahn joins Noxilizer after over 20 years in health care companies, including Eli Lilly and Company and MedImmune, Inc.

“Maura brings a wealth of experience in identifying potential partners, developing win-win partnerships, launching new products and running multi billion-dollar pharmaceutical and biotech product businesses. She clearly understands the opportunities and challenges of managing a product pipeline and how Noxilizer’s technology can serve as a way to enable the next generation of breakthrough products that can meet important patient needs,” said Marie-Louise Murville, President and COO of Noxilizer. “She will play a key role in securing partnerships with targeted biotherapeutic companies, marketing the Noxilizer sterilizers for hospitals, and fundraising.”

Maura joins Noxilizer from MedImmune, Inc, where she served as Senior Director of Marketing for Infectious Disease. During her tenure at MedImmune, she was responsible for developing and executing the marketing strategy and plan for Synagis and pre-launch plan for MedI-524. Prior to joining MedImmune in 2004, Maura spent nine years at Eli Lilly and Company in US Diabetes Marketing, Sales Management, Business Development and Global New Product Planning. She was a member of the US Humalog launch team, led the US launch of the Humulin/Humalog Pen and initiated the first ever direct-to-consumer campaign at Lilly. In addition, she was a member of the deal teams in Lilly’s successful negotiations with Takeda for Actos and Amylin for Byetta.

She began her career at Targeted Communications (an Ogilvy & Mather Direct company) and, later, The RTC Group (a WPP company) both located in Washington, DC. Her clients included political candidates, trade associations and Fortune 500 companies. She has worked on legislative issues on the local, state and federal level, as well as some of the first direct-to-consumer campaigns in the pharmaceutical industry.

Maura received her Bachelor of Arts from Saint Mary’s College in Indiana and her Master’s of Business Administration from Indiana University.

[ back to top ]

Noxilizer Advantages Presented in Biomedical Materials Journal

Feb 2008

In a recently published article by C.M. Yakacki et al. in the journal Biomedical Materials Noxilizer sterilization was compared to Steam, ETO, Irradiation and the Sterrad Low Temperature Process (LTP) processes on two shape memory polymers manufactured by Medshape Solutions, Inc. for cytotoxicity and thermomechanical properties. These polymers have future applications as cardiovascular stents and orthopedic fixation devices. The results showed that the samples exposed to the LTP process had a significant cytotoxic response, unlike the Noxilizer sterilized materials which were comparable to the control unexposed samples. This finding has important implications for the future development of the next generation of medical devices. According to Yakacki, the Noxilizer sterilization process may provide a truly cold sterilization process and would be a critical enabling technology in the advancement of important medical devices that address unmet patient needs.

[ back to top ]

Noxilizer Announces Appointment of David Opie, Ph.D. as Vice President, Research and Development

Sept 2007

Bethesda, MD, September 19, 2007 – Noxilizer, Inc., a developer of next-generation gas sterilization systems for advanced drug-device combination products, announced today the appointment of David Opie, Ph.D., as Vice President, Research and Development. Dr. Opie joins Noxilier after a 20-year career in start-up and leading medical products companies, including Johnson & Johnson and Cook Medical.

“David brings a wealth of expertise in the development and manufacturing of advanced medical products such as biologic devices, and medical implants where sterilization is a growing challenge and where our technology offers key advantages over current methods,” said Marie-Louise Murville, President and COO of Noxilizer. “He will play a key role in advancing the development and commercialization of our sterilization system.”

Dr. Opie joins Noxilizer from the Cook Medical/Med Institute where he served as Scientific Liaison to the President. Previously, he served in senior positions at several medical device startups, including Liquidmetal Technologies, Inc. (Vice President for Products and Processes); Angiosense, Inc. (President and CEO); and Exion, Ltd. (Vice President of U.S. Operations). Prior to Exion, he served at two Johnson & Johnson companies, Biosense Webster (Group Manager for Business and Procedure Development) and Ethicon Endo-Surgery (Principal Scientist).

Dr. Opie holds a Ph.D. and an M.S. in Physics from the College of William and Mary, and a BA in Physics from the University of Delaware.

About Noxilizer, Inc.
Noxilizer is pioneering the development and commercialization of a superior gas sterilization system to enable the terminal sterilization of advanced drug-device combination products. The Company’s proprietary method, which sterilizes at room temperature, has demonstrated great potential for use with a wide range of devices, including products for drug delivery that combine resorbable polymers and therapeutic molecules. The lack of such a cost-effective sterilization process for this large and emerging class of products has become a development and commercial barrier. Noxilizer is developing its system for both in-line manufacturing and point-of-use applications. Learn more at www.noxilizer.com.

[ back to top ]